943541-20-6

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine is used as an antiviral agent for its ability to inhibit the replication of viral RNA, making it a potential candidate for treating various viral infections such as influenza, Ebola virus, and SARS-CoV-2.
Used in Oncology Research:
In the field of oncology, 3-Chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine is utilized as an antitumor agent due to its potential to combat cancer cells, offering a new avenue for cancer treatment strategies.
Used in Preclinical Studies:
3-Chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine serves as a subject of preclinical studies to evaluate its efficacy, safety, and potential side effects in treating the aforementioned diseases, ensuring a thorough understanding of its applications before moving to clinical trials.

Upstream product

• 141-30-0 3,6-dichlorpyridazine 
• 761446-44-0 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1440965-04-7 3-chloro-6-(1-trityl-1H-pyrazol-4-yl)pyridazine 
• 1211519-08-2 3-chloro-6-(1H-pyrazol-4-yl)pyridazine 
• 75-26-3 isopropyl bromide 
• 74-88-4 methyl iodide 
• 1121-79-5 3-chloro-6-methylpyridazine 
• 60-34-4 methylhydrazine 
• 847818-55-7 (1-methyl-1H-pyrazol-4-yl)boronic acid 
• 135034-10-5 3-chloro-6-iodopyridazine 

Downstream Products

• 943540-75-8 JNJ-38877605 
• 1357072-61-7 6-(1-methyl-1H-pyrazol-4-yl)-3-(2-methyl-2H-indazol-5-ylthio)-[1,2,4]triazolo[4,3-b]pyridazine 
• 1233361-22-2 N-ethyl-2-(2-{3-[3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)acetamide 
• 1233361-57-3 (2-{3-[3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)acetyl chloride 
• 1233361-56-2 (2-{3-[3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)-acetic acid 
• 1233361-55-1 (2-{3-[3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)acetic acid methyl ester 
• 1233361-64-2 2-{3-[5-(2,3-dihydroxypropoxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one 
• 1233361-16-4 2-{3-[5-(3-hydroxycyclopentyloxy)pyrimidin-2-yl]benzyl}-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one 
• 1233361-26-6 tert-butyl [2-(2-{3-[3-(1-methyl-1H-pyrazol-4-yl)-6-oxo-6H-pyridazin-1-ylmethyl]phenyl}pyrimidin-5-yloxy)ethyl]carbamate 
• 1100598-43-3 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyrimidin-2-yl]benzyl}-2H-pyridazin-3-one 
• 1100598-44-4 2-[3-(5-hydroxypyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one 
• 1100598-42-2 2-[3-(5-bromo-pyrimidin-2-yl)benzyl]-6-(1-methyl-1H-pyrazol-4-yl)-2H-pyridazin-3-one 
• 1201930-20-2 3-[(3-bromophenyl)difluoromethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1201930-17-7 3-(3-bromobenzyl)-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo-[4,3-b]pyridazine 

Relevant academic research and scientific papers

Preparation method and intermediate of pyrazole compound

The invention discloses a preparation method and an intermediate of a pyrazole compound. The invention specifically discloses a preparation method of a compound B. The preparation method provided by the invention has one or more advantages as follows: the operation is simple, the yield is relatively high, the cost is low, and the method is suitable for industrial production.

Quindoline derivative, medicine composition thereof, preparation method and application

The invention discloses a quindoline derivative, a medicine composition thereof, a preparation method and application. The quindoline derivative has c-Met inhibition activity and can be used for treating, alleviating and/or preventing cancerous or similar diseases. (See the specification).

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.

A DEUTERATED TRIAZOLOPYRIDAZINE AS A KINASE MODULATOR

The invention is directed to a triazolopyridazine compound of formula (I), N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS

The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

COMPOUND USEFUL AS A C-MET INHIBITOR

The present invention relates to a c-Met inhibitor (disclosed herein) or a pharmaceutically acceptable salt thereof useful in treating cancer mediated by activity of c-Met receptors.

3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS

Compounds of the formula (I), in which R1, R2, R3, R3′, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.

PYRIDAZINONE DERIVATIVES

Compounds of the formula (I), in which Y, R1, R2, R3 and R3′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.

POLYMORPHIC AND HYDRATE FORMS, SALTS AND PROCESS FOR PREPARING 6-{DIFLUORO[6-(1-METHYL-1H-PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]METHYL}QUINOLINE

The invention relates to novel polymorphic and hydrate forms and salts of 6-{difluoro[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline, to methods for their preparation, to pharmaceutical compositions comprising at least one of said polymorphic or hydrate forms or salts, and to the therapeutic and/or prophylactic use of such compositions. The invention also provides new manners for preparing said compound.